Treatment of male genital tuberculosis in genitourinary tuberculosis with multidrug resistance
When male genital tuberculosis arises as part of genitourinary TB and the organism is resistant to both rifampicin and isoniazid, this constitutes multidrug-resistant TB (MDR-TB). Standard first-line regimens are inadequate in this setting and a different treatment strategy is required.
Clinical scenario: Genitourinary tuberculosis with confirmed multidrug resistance — resistance to both rifampicin and isoniazid. This resistance profile defines MDR-TB and rules out standard first-line treatment.
Treatment approach (partial overview): Management requires an individualised treatment regimen composed of at least five effective tuberculosis medicines during the intensive phase. Pyrazinamide is included alongside a combination of second-line agents drawn from several distinct drug groups. The complete regimen — including which agents are selected, how they are combined, and applicable exceptions — is set out in the full structured protocol.
References
- For the treatment of multidrug-resistant (MDR) TB (i.e. resistance to rifampicin and isoniazid), an individualised treatment regimen should be applied with at least five effective tuberculosis medicines during the intensive phase, including pyrazinamide and four core second-line tuberculosis medicines.
- Treat multidrug-resistant TB with an individualised treatment regimen including at least five effective tuberculosis medicines during the intensive phase, including pyrazinamide and four core, second-line tuberculosis medicines.
- Drugs should be chosen as follows: one from group A, one from group B and at least two from group C. If the minimum number of five TB medicines cannot be composed from drugs included in Groups A to C, an agent from group D2 and other agents from group D3 can be added to bring the total to five.